Teixeira et al., 2018 - Google Patents
Quality assessment of prognostic studies using cancer stem cell markers in oral squamous cell carcinomaTeixeira et al., 2018
- Document ID
- 916624251650050579
- Author
- Teixeira M
- Corrêa L
- Publication year
- Publication venue
- Applied Immunohistochemistry & Molecular Morphology
External Links
Snippet
Cancer stem cells (CSC) have been investigated as prognostic markers in oral squamous cell carcinoma (OSCC). However, an assessment of the reporting quality of these studies has not been performed yet. The aim of this study was to describe the reporting quality of …
- 201000002740 oral squamous cell carcinoma 0 title abstract description 45
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Clay et al. | MDM2 and CDK4 immunohistochemistry: should it be used in problematic differentiated lipomatous tumors?: a new perspective | |
| Righi et al. | Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine‐needle aspiration cytology: a retrospective study of 103 cases with surgical correlation | |
| Hameed et al. | Immunohistochemical stains for p63 and α-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues | |
| Raynaud et al. | DNA damage repair and telomere length in normal breast, preneoplastic lesions, and invasive cancer | |
| Sedaghat et al. | Expression of cancer stem cell markers OCT4 and CD133 in transitional cell carcinomas | |
| Lacoste‐Collin et al. | Improvement of the cytological diagnostic accuracy of follicular thyroid lesions by the use of the K i‐67 proliferative index in addition to cytokeratin‐19 and HBME‐1 immunomarkers: a study of 61 cases of liquid‐based FNA cytology with histological controls | |
| Zbytek et al. | Nottingham-defined mitotic score: comparison with visual and image cytometric phosphohistone H3 labeling indices and correlation with Oncotype DX recurrence score | |
| Warrick et al. | Foamy gland carcinoma of the prostate in needle biopsy: incidence, Gleason grade, and comparative α-methylacyl-CoA racemase vs. ERG expression | |
| Zen et al. | Elevated K i‐67 labeling index in ‘synchronous liver metastases’ of well differentiated enteropancreatic neuroendocrine tumor | |
| Tao et al. | Clinical significance of circulating tumor cells in breast cancer patients | |
| He et al. | p16 immunohistochemistry as an alternative marker to distinguish atypical lipomatous tumor from deep-seated lipoma | |
| Hattori et al. | Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung | |
| Önal et al. | The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer—institutional experience and review | |
| May et al. | Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy | |
| Idrees et al. | Immunoexpression of oral brush biopsy enhances the accuracy of diagnosis for oral lichen planus and lichenoid lesions | |
| Kunju et al. | Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl‐CoA racemase (AMACR) in the work‐up of prostate cancer | |
| Smits et al. | Different cutoff values for thyroid transcription factor-1 antibodies in the diagnosis of lung adenocarcinoma | |
| Snow et al. | Prostate‐specific membrane antigen expression in melanoma metastases | |
| Itoguchi et al. | Immunocytochemical staining for stratifin and OCIAD 2 in bronchial washing specimens increases sensitivity for diagnosis of lung cancer | |
| Gustavson et al. | Development of an unsupervised pixel-based clustering algorithm for compartmentalization of immunohistochemical expression using Automated QUantitative Analysis | |
| Knapp et al. | Expression of CXCR4, E-cadherin, Bcl-2, and survivin in Merkel cell carcinoma: an immunohistochemical study using a tissue microarray | |
| Teixeira et al. | Quality assessment of prognostic studies using cancer stem cell markers in oral squamous cell carcinoma | |
| Raman et al. | Utility of smooth muscle actin and CD117 as reliable markers in the diagnosis of salivary gland neoplasms | |
| Wangerin et al. | CD57 expression in incidental, clinically manifest, and metastatic carcinoma of the prostate | |
| Pierga et al. | Clinical significance of proliferative potential of occult metastatic cells in bone marrow of patients with breast cancer |